» Articles » PMID: 16038822

Pancreaticojejunal Anastomosis is Preferable to Pancreaticogastrostomy After Pancreaticoduodenectomy for Longterm Outcomes of Pancreatic Exocrine Function

Overview
Journal J Am Coll Surg
Date 2005 Jul 26
PMID 16038822
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The aim of this study was to evaluate pancreatic exocrine and endocrine function after pancreaticoduodenectomy.

Study Design: Pancreatic exocrine function was evaluated by a questionnaire and medical examination of stools after discontinuing pancreatic enzyme supplements for at least 10 days. Severe steatorrhea was defined as frequent, nauseating, yellow, and pasty stools, fecal output >200 g/d for more than 3 days. Endocrine function was evaluated by blood glucose level. Association between severe steatorrhea and age, indication, histologic obstructive pancreatitis, pancreaticojejunal anastomosis (PJA), pancreaticogastric anastomosis (PGA), and morbidity was studied.

Results: Fifty-two patients underwent pancreaticoduodenectomy, complication rate was 33%. PJA was performed in 41 patients (79%) and PGA in 11 patients (21%). At a median followup of 75 months (24 to 156 months), 65% of the patients received pancreatic enzyme supplements. Severe steatorrhea was observed in 22 patients (42%). Incidence of postoperative diabetes was 14.6%. Patient age (more than 60 years), postoperative complication, and obstructive pancreatitis were not associated with postoperative severe steatorrhea. In cases of nonhistologic obstructive pancreatitis, PGA was more frequently associated with severe steatorrhea than PJA (70% versus 21.7%, p < 0.025). No factor significantly influenced incidence of postoperative diabetes.

Conclusions: After pancreaticoduodenectomy, 42% of patients presented with severe steatorrhea. PJA allows better pancreatic exocrine function preservation than PGA and should be recommended.

Citing Articles

Functional, biological, and radiological evaluation of the pancreaticojejunal anastomosis 1 year after pancreatoduodenectomy: a prospective study.

Joliat G, Allemann P, Labgaa I, Demartines N, Violi N, Schmidt S Langenbecks Arch Surg. 2023; 408(1):326.

PMID: 37606699 PMC: 10444682. DOI: 10.1007/s00423-023-03040-x.


Challenges in Diagnosis and Treatment of Pancreatic Exocrine Insufficiency among Patients with Pancreatic Ductal Adenocarcinoma.

Lan X, Robin G, Kasnik J, Wong G, Abdel-Rahman O Cancers (Basel). 2023; 15(4).

PMID: 36831673 PMC: 9953920. DOI: 10.3390/cancers15041331.


Risk factors for exocrine pancreatic insufficiency after pancreatic surgery: a systematic review and meta-analysis.

Budipramana V, Witarto A, Witarto B, Pramudito S, Ratri L, Wairooy N Can J Surg. 2022; 65(6):E770-E781.

PMID: 36384688 PMC: 9671296. DOI: 10.1503/cjs.010621.


Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board.

Rovesti G, Valoriani F, Rimini M, Bardasi C, Ballarin R, Di Benedetto F Nutrients. 2021; 13(10).

PMID: 34684523 PMC: 8537095. DOI: 10.3390/nu13103522.


Pancreatic outflow tract reconstruction after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials.

Wang X, Yan Y, Dong B, Li Y, Yang X World J Surg Oncol. 2021; 19(1):203.

PMID: 34229720 PMC: 8262038. DOI: 10.1186/s12957-021-02314-2.